import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "where-to-buy-cjc-1295-with-dac-research-guide",
  title: "Where to Buy CJC-1295 with DAC: A Researcher's Sourcing Guide",
  description:
    "CJC-1295 with DAC (Drug Affinity Complex) is the long-acting GHRH analog with a half-life of 6–8 days, enabling once- or twice-weekly dosing in extended research protocols. This guide covers what researchers need to verify before purchasing — DAC modification confirmation, purity standards, COA requirements, and how to distinguish legitimate CJC-1295 DAC from the far more common no-DAC variant.",
  category: "Quality & Testing",
  readMinutes: 9,
  publishedAt: "2026-06-07",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "CJC-1295 with DAC is the most misrepresented GHRH analog in the research peptide market. The 'DAC' modification — Drug Affinity Complex, a maleimidopropionic acid (MPA) lysine conjugate — dramatically extends the compound's biological half-life from approximately 30 minutes (CJC-1295 without DAC) to 6–8 days by enabling covalent binding to circulating albumin. It is a fundamentally different research compound from the no-DAC version, with different dosing protocols, different research applications, and critically — a different synthesis process that most commodity suppliers have not properly characterized.",
    },
    {
      type: "heading",
      text: "CJC-1295 DAC vs. CJC-1295 No-DAC: The Core Distinction",
    },
    {
      type: "paragraph",
      text: "Both compounds share the same modified GHRH(1-29) backbone: a 29-amino acid sequence with tetrasubstituted amino acid analogs at positions 2 and 8 for DPP-IV resistance. The critical difference is the C-terminal modification: in CJC-1295 with DAC, a lysine residue at the C-terminus carries the maleimidopropionic acid group that enables albumin binding. Without this modification, the compound is CJC-1295 no-DAC (also called Modified GRF 1-29).",
    },
    {
      type: "paragraph",
      text: "From a research protocol perspective, these two compounds are not interchangeable. CJC-1295 no-DAC is designed for pulsatile GH release and is typically studied in injection protocols mimicking the natural GHRH-GH pulsatile pattern. CJC-1295 with DAC is studied in protocols designed for sustained GH axis stimulation, with administration intervals of days rather than hours. Researchers who order one and receive the other will observe completely different pharmacokinetic and GH pulse profiles in their models.",
    },
    {
      type: "heading",
      text: "Why Verification of the DAC Modification Is Critical",
    },
    {
      type: "paragraph",
      text: "The DAC modification adds a maleimidopropionic acid (MPA) conjugate to the epsilon-amine of a C-terminal lysine residue. This modification changes the molecular weight of the compound from approximately 3367 Da (no-DAC form) to approximately 3647 Da (DAC form). The difference is approximately 280 Da — readily distinguishable by mass spectrometry.",
    },
    {
      type: "paragraph",
      text: "Mass spectrometry confirmation of the DAC form is therefore the single most important analytical test on the COA. An ESI-MS or MALDI-TOF result showing the expected [M+H]⁺ molecular ion near 3647 Da (or the appropriate multiply-charged ions for ESI-MS) confirms the DAC modification is present. A result near 3367 Da confirms you received the no-DAC form. Any COA that does not include MS data cannot confirm which compound is in the vial — HPLC chromatography alone cannot distinguish them without a reference standard comparison.",
    },
    {
      type: "heading",
      text: "COA Requirements for Research-Grade CJC-1295 with DAC",
    },
    {
      type: "paragraph",
      text: "The minimum documentation standard for CJC-1295 with DAC is higher than for simpler peptides, precisely because the chemical modification must be explicitly confirmed. A complete COA should contain:",
    },
    {
      type: "list",
      items: [
        "Lot/batch number matching the vial",
        "Compound name explicitly stating 'CJC-1295 with DAC' or 'CJC-1295 DAC' — not just 'CJC-1295'",
        "Theoretical molecular weight: ~3647 Da (DAC form) — the COA should state this explicitly",
        "Mass spectrometry: ESI-MS or MALDI-TOF confirming MW ~3647 Da — this is the DAC confirmation test",
        "HPLC purity ≥98% with full chromatogram showing retention time, peak area table, and method conditions",
        "Karl Fischer water content for accurate mass-to-molar dosing calculations",
        "Endotoxin (LAL) result if the compound will be used in in vivo or cell culture research",
        "Named, accredited independent third-party laboratory — not an in-house testing facility",
        "Test date within 18 months of intended use",
      ],
    },
    {
      type: "paragraph",
      text: "Any COA that does not confirm the molecular weight to the DAC form, that lists only 'CJC-1295' without DAC specification, or that provides an HPLC result without MS confirmation should be treated as unverified. The consequences of receiving no-DAC product when a DAC protocol was designed can include complete failure of the protocol — sustained GH stimulation simply will not occur.",
    },
    {
      type: "heading",
      text: "Synthesis and Purity Challenges Specific to CJC-1295 DAC",
    },
    {
      type: "paragraph",
      text: "Synthesizing CJC-1295 with DAC requires two distinct production steps: first, SPPS synthesis of the 29-AA modified GHRH backbone, and second, conjugation chemistry to attach the MPA-DAC group to the C-terminal lysine. The conjugation step introduces additional potential impurities, including unconjugated backbone peptide (which will appear as the no-DAC form in MS), bis-conjugated byproducts, and hydrolyzed maleimide degradation products.",
    },
    {
      type: "paragraph",
      text: "A well-characterized CJC-1295 DAC product should show in the HPLC chromatogram a single dominant peak corresponding to the DAC-conjugated form, with the no-DAC form either absent or present as a minor peak below 1–2%. Suppliers who do not perform conjugation efficiency testing — or who do not separate the no-DAC backbone from the conjugated product during purification — will produce a blend rather than a pure DAC compound. Researchers examining sustained GH profiles may see inconsistent results that reflect a mixed population of compounds with different half-life profiles.",
    },
    {
      type: "heading",
      text: "Storage and Stability Considerations",
    },
    {
      type: "paragraph",
      text: "CJC-1295 with DAC is more labile than many simpler peptides due to the reactive maleimide functionality of the DAC group. The maleimide can hydrolyze to the open-ring maleamic acid form, which loses its albumin-binding ability. This hydrolysis is accelerated by elevated temperature, moisture, and alkaline pH conditions.",
    },
    {
      type: "paragraph",
      text: "Storage requirements: lyophilized CJC-1295 DAC should be stored at -20°C, protected from moisture and light. Reconstitution should be performed with sterile bacteriostatic water (0.9% benzyl alcohol) at neutral pH — alkaline reconstitution solvents accelerate maleimide hydrolysis. Once reconstituted, stability at 4°C is typically 14–30 days depending on initial product quality. A supplier who ships CJC-1295 DAC without cold-chain measures is accelerating maleimide hydrolysis in transit and delivering a compound with reduced DAC functionality.",
    },
    {
      type: "heading",
      text: "Red Flags in the CJC-1295 DAC Market",
    },
    {
      type: "list",
      items: [
        "COA labeled 'CJC-1295' without specifying whether DAC form or no-DAC — cannot determine which compound",
        "No mass spectrometry data — the only reliable method to confirm the DAC modification",
        "MS result showing MW ~3367 Da — confirms you would receive no-DAC form despite DAC labeling",
        "HPLC showing significant secondary peaks — may indicate incomplete DAC conjugation and no-DAC backbone contamination",
        "Pricing at no-DAC commodity levels — CJC-1295 DAC synthesis requires additional conjugation steps and costs more to produce correctly",
        "No cold-chain shipping — accelerates maleimide hydrolysis and destroys the albumin-binding functionality",
        "Supplier unable to confirm which MW their 'CJC-1295' product has",
        "COA test date older than 24 months for a compound with labile reactive chemistry",
      ],
    },
    {
      type: "heading",
      text: "Confirming Identity Before Your Protocol Begins",
    },
    {
      type: "paragraph",
      text: "Before designing a sustained GH stimulation protocol around CJC-1295 with DAC, verify the compound identity from the supplier's COA. The question to ask directly: 'Does the MS data on the COA confirm MW ~3647 Da, corresponding to the DAC conjugated form?' If the supplier cannot produce an MS number near 3647 Da, they have not confirmed they are selling the DAC compound. The research protocol built around 6–8 day half-life kinetics will not perform as expected with a no-DAC product.",
    },
    {
      type: "callout",
      text: "At Nexphoria, CJC-1295 with DAC is analytically characterized with explicit DAC confirmation: mass spectrometry showing MW ~3647 Da, HPLC ≥98% with full chromatogram, Karl Fischer water content, and endotoxin testing — all from independent US-based third-party laboratories. We confirm the DAC form on every lot. Cold-chain shipping on every order.",
    },
    {
      type: "disclaimer",
      text: "CJC-1295 with DAC and all compounds on the Nexphoria platform are sold exclusively for licensed laboratory research. Not for human consumption. Not for use in animals outside approved IACUC protocols. Compliance with all applicable federal and state regulations is the sole responsibility of the purchasing researcher.",
    },
  ],
};
